Company Overview and News

1
10 Monthly Dividend Stocks to Buy to Pay the Bills

2h investorplace
I like making money in the stock market, but I love dividends. You see, the problem with capital gains is that to actually enjoy them, you have to sell your shares. The beauty of dividend stocks is that you get to enjoy the fruits of your investment without having to actually sell anything. Think of it as milking a cow rather than killing it for meat. Which sounds like the better long-term plan to you?
RNP EVV O MAIN LTC OPRF PSEC VER MSCA.CL EPR MSCA PBB STAG

 
Main Street Capital: Don't Fear The Premium

2018-09-21 seekingalpha
A couple of recent articles tried to cast doubt on the long term prospects of the premium to NAV that Main Street trades at today.
MSCA.CL MSCA MAIN

8
Potentially Oversold Best Of Breed BDC: Initiating Coverage

2018-09-19 seekingalpha
Earlier this year, I initiated active coverage of GAIN (8.2% yield) and its preferred stocks GAINM (6.2% yield) and now its newly issued GAINL (6.3% yield).
AIY AINV CLA GAIN GAINM MCQ KAP PNNT BKCC MCV PFLT OSLE GADDP GAINL GLADO HTGZ KCAP GLAD ABDC MSCA CPTA MCC TCRX ARCC HCAPL FSIC MAIN TCPC AIB TCRD TCRZ PSEC HTGX NMFC HTGY TSLF OCSI ARU OCSL MSCA.CL MCX HCAP SUNS HTGC PBB PNTA

1
Ares Capital: Should Dividend Growth Investors Consider It?

2018-09-18 seekingalpha
ARCC does not have a history of dividend growth, but it does have a history of paying a dividend.
ARU MSCA.CL ARCC MSCA MAIN

3
Prospect Capital's Detailed Dividend And NAV Sustainability Analysis - Part 1 (Includes Remaining Fiscal Year 2019 Monthly Dividend Projection)

2018-09-17 seekingalpha
Following continued requests due to recent earnings, Part 1 of this article analyzes PSEC's dividend sustainability by performing three tests based on recent (and projected) quarterly results.
ARCC MAIN GAIN GAINM GADDP PSEC NEWTZ ARU MSCA.CL SLRC MSCA TSLX NEWT NEWTL PBB SLRA MO

 
The MnM Portfolio, August 2018 - Reintroducing An Old Friend To The Portfolio

2018-09-16 seekingalpha
This month's article marks the forty-second installment in my ongoing series outlining my efforts to achieve dividend growth success. The portfolio is nicknamed the MnM portfolio, which is a moniker for "Minne(sota) 'n Monthly."
UNM VIG MSCA.CL MSCA MAIN ITW O OPRF

1
Why We Don't Own The Best Performing BDC

2018-09-13 seekingalpha
We breakdown the returns and tell you why the numbers are pulling a fast one on you.
MSCA.CL MSCA MAIN GAIN GAINM GADDP

2
Should You Invest in the VanEck Vectors BDC Income ETF (BIZD)?

2018-09-13 zacks
Launched on 02/11/2013, the VanEck Vectors BDC Income ETF (BIZD - Free Report) is a passively managed exchange traded fund designed to provide a broad exposure to the Financials - BDCs/PE segment of the equity market.
ARU MSCA.CL ARKG ARCC MSCA MAIN AMZA PBB PSEC ARKK

6
Main Street Capital's NAV, Dividend, And Valuation Compared To 14 BDC Peers (Post Q2 2018 Earnings) - Part 2

2018-09-13 seekingalpha
Part 2 of this article compares MAIN’s recent dividend per share rates, yield percentages, and several other dividend sustainability metrics to fourteen other BDC peers.
AIY AINV GAIN MCQ GAINM MCV OSLE GADDP SLRC MSCA TSLX NEWT SLRA MO MCC ARCC GBDC FSIC MAIN TCPC AIB PSEC NEWTZ ARU OCSL MSCA.CL MCX BLK MDLY NEWTL PBB

 
3 High-Yield, Monthly Dividend Stocks To Fund A Prosperous Retirement

2018-09-12 seekingalpha
High-yield monthly dividend stocks can be a great way to pay the bills, especially in retirement.
MSCA.CL MSCA MAIN O SPG OPRF

 
Main Street Capital: Still The Best

2018-09-11 seekingalpha
How do you improve a dividend growth company paying a well supported monthly dividend? Increase the dividend.
MSCA.CL MSCA MAIN

 
Main Street Capital Is A Strong Sell As Its 67% Premium Is Dangerous, Unwarranted, And Unsustainable

2018-09-10 seekingalpha
MAIN is a best of breed BDC which has seen consistent increases to NAV and their regular dividend payout.
MSCA.CL MSCA MAIN

4
Prospect Capital's NAV, Valuation, And Dividend Compared To 14 BDC Peers (Post Q2 2018 Earnings)

2018-09-10 seekingalpha
Following multiple requests, this “supplemental” article compares PSEC’s recent quarterly change in NAV, quarterly and trailing twelve-month economic return, NII, and current valuation to 14 BDC peers.
AIY AINV GAIN MCQ GAINM MCV PFLT OSLE GADDP SLRC MSCA TSLX NEWT SLRA MO MCC ARCC GBDC MAIN TCPC AIB PSEC NEWTZ ARU OCSL MSCA.CL MCX BLK NEWTL PBB

1
A Full Analysis Of Prospect Capital's Results For Fiscal Q4 2018 (2 Recent Cautionary Trends)

2018-09-06 seekingalpha
On 8/28/2018, PSEC reported results for the fiscal fourth quarter of 2018. PSEC reported NII, earnings, and a NAV as of 6/30/2018 of $0.219, $0.315, and $9.349 per share, respectively.
MSCA.CL MSCA MAIN TSLX PBB PSEC MO

5
High-Yield BDC Sector Return And Expense Ratios

2018-09-04 seekingalpha
This article compares the return and expense ratios for the BDC sector so that investors can identify which companies are efficiently able to distribute higher returns to shareholders.
CLA MCQ MRCC MCV PFLT OSLE HTGZ ABDC MSCA TSLX CPTA MCC GSBD TCRX GBDC MAIN TCRD TCRZ PSEC HTGX TSLF HTGY OCSI OCSL MSCA.CL MCX SUNS HTGC PBB

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

CUSIP: 56035L302